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Abstract
Several inflammatory cytokines are involved in vascular inflammation resulting in endothelial
dysfunction which is the earliest event in the atherosclerotic process leading to manifest
cardiovascular disease. YKL-40 is an inflammatory glycoprotein involved in endothelial dysfunction
by promoting chemotaxis, cell attachment and migration, reorganization and tissue remodelling as
a response to endothelial damage. YKL-40 protein expression is seen in macrophages and smooth
muscle cells in atherosclerotic plaques with the highest expression seen in macrophages in the early
lesion of atherosclerosis. Several studies demonstrate, that elevated serum YKL-levels are
independently associated with the presence and extent of coronary artery disease and even higher
YKL-40 levels are documented in patients with myocardial infarction. Moreover, elevated serum
YKL-40 levels have also been found to be associated with all-cause as well as cardiovascular
mortality. Finally, YKL-40 levels are elevated both in patients with type 1 and type 2 diabetes,
known to be at high risk for the development of cardiovascular diseases, when compared to non-
diabetic persons. A positive association between elevated circulating YKL-40 levels and increasing
levels of albuminuria have been described in patients with type 1 diabetes indicating a role of YKL-
40 in the progressing vascular damage resulting in microvascular disease.
This review describes the present knowledge about YKL-40 and discusses its relation to endothelial
dysfunction, atherosclerosis, cardiovascular disease and diabetes and look ahead on future
perspectives of YKL-40 research.
Introduction
Since the results of the Framingham Heart Study revealed
C-reactive protein (CRP) as a cardiovascular marker even
in ranges considered normal [1-3], several studies of
biomarkers in cardiovascular disease (CVD) have been
conducted. Until this day, CRP remains the most vali-
dated biomarker but substantial knowledge about CRP as
a predictor of cardiovascular events is now complemented
by studies of new emerging markers such as interleukin
18, matrix metalloproteinase 9, adiponectin and CD40
ligand [4]. The present review focuses on the inflamma-
tory protein YKL-40 and its role in atherosclerosis, CVD
and diabetes.
YKL-40 - biology and physiology in general
YKL-40 is a 40 kDa heparin- and chitin-binding glycopro-
tein also known as human cartilage glycoprotein 39 (HC-
gp39) [5], 38-kDa heparin-binding glycoprotein [6] or
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chitinase-3-like protein 1 (CHI3L1) [7]. The abbreviation
YKL-40 is based on the one letter code for the first three N-
terminal amino acids, tyrosine (Y), lysine (K) and leucine
(L) and the apparent molecular weight of YKL-40 [8].
The  CHI3L1  gene for human YKL-40 is localized in a
highly conserved area on chromosome 1q31-q32 [9] and
the crystal structure of YKL-40 has been described [10].
YKL-40 belongs to the family 18 of glycosyl hydrolases
comprising chitinases from various species [11], but YKL-
40 is without any enzymatic properties [5,12,13].
YKL-40 is secreted in vitro by a variety of cells and seems
especially involved in activation of the innate immune
system and in cell processes in relation to extracellular
matrix remodelling [11,14]. YKL-40 induce the matura-
tion of monocytes to macrophages, and is secreted by
macrophages during late stages of differentiation and by
activated macrophages [7,15-18]. Studies show that the
differentiation and maturation of CD14+ monocytes to
CD14-, CD16+ macrophages are attended by an expres-
sion of YKL-40 from CD16+ macrophages [17]. YKL-40
has also been shown to be an adhesion and migration fac-
tor for vascular cells and is secernated by differentiated
vascular smooth muscle cells (VSMCs) [6,19,20]. In vivo
YKL-40 protein expression is found in human VSMCs in
adventitial vessels [21] and in subpopulations of macro-
phages and VSMCs in different tissues with inflammation
and extracellular matrix remodelling as in atherosclerotic
plaques [14,19,22].
The knowledge about the physiological function and the
mechanisms by which YKL-40 mediates its effects is still
scarce. Immunohistochemical studies of different types of
normal human tissues show, that cells with a high cellular
activity, e.g. a high level of metabolic activity and/or pro-
liferation, have especially high YKL-40 expression [23,24].
YKL-40 mRNA and protein expression are found in tissues
from all germ layers and are present during the early
development of the human musculoskeletal system where
they seem associated with cell proliferation, differentia-
tion and tissue morphogenesis [23]. Other studies show,
that YKL-40 stimulates the proliferation of human con-
nective tissue cells (fibroblasts, chondrocytes, synovial
cells) in a dose-dependent manner in a functional concen-
tration range similar to that of insulin-like growth factor
(IGF-1). When present in suboptimal concentrations,
YKL-40 and IGF-1 work in a synergistic fashion [25,26]. In
mouse studies, YKL-40 stimulates the antigen-induced T-
helper 2-response and seems to induce tissue inflamma-
tion and fibrosis mediated by IL-13. In this sense, YKL-40
plays an essential role in antigen sensitization and IgE
induction as well as in activation of innate immune cells
[27].
In fibroblasts and synovial cells YKL-40 mediates a
mitogenic effect through initiation of mitogen-activated
protein kinase (MAPK) and phosphoinoside-3 kinase
(PI3K) signalling pathways by phosphorylation of the
extracellular signal-regulated kinase-1 and 2 (ERK1/
ERK2) and protein kinase B (AKT), respectively. Both
pathways are required for the cells to complete mitosis
and the activation of these pathways stimulates the
growth of connective tissue cells [26].
In fibroblasts and chondrocytes YKL-40 reduces the acti-
vation of p38 and SAPK/JNK MAPKs which counteracts
the inflammatory responses to TNFα and IL-1. This leads
to reduced concentrations of matrix metalloproteinases
(MMPs) and IL-8. The modulation of p38 and SAPK/JNK
by YKL-40 is mediated through the PI3K [28] and the
induction and continued secretion of YKL-40 require sus-
tained activation of Nf-κB [29]. YKL-40 has no effect on
the signalling pathways p38 and SAPK/JNK MAPKs when
present without the presence of TNFα and IL-1 and simi-
lar do not affect the MMP or IL-8 production. This sug-
gests that YKL-40 expression is an anti-inflammatory
counteract of the inflammatory response mediated by
TNFα and IL-1 [28] beside its apparent function as a
growth factor [26]. The activation of cytoplasmatic signal-
transduction pathways suggests, that YKL-40 interacts
with one or several signalling components on the plasma
membrane. However, specific cell surface receptors or
potential YKL-40 ligands remain to be determined.
No difference in serum or plasma YKL-40 levels has been
found between genders [11]. In serum, no significant
diurnal, weekly or long-time variation in serum YKL-40
concentrations are found in healthy subjects [30]. Simi-
larly, serum YKL-40 concentrations are not affected by
physical exercise [30]. There seems to be no or only weak
correlation between YKL-40 and hsCRP in studies of
patients with diabetes, obesity or atrial fibrillation [31-34]
whereas a positive correlation is found between YKL-40
and hsCRP in studies of patients with manifest coronary
artery disease (CAD) [35,36]. Opposite CRP which is a
systemic inflammation marker primarily secreted by
hepatocytes in response to proinflammatory mediators
such as IL-6, YKL-40 is locally produced and secernated.
However, all studies investigating the association between
YKL-40 and IL-6 found a positive correlation between the
two [34,37,38]. Furthermore, a tight association between
monocyte chemoatractant protein-1 (MCP-1) and YKL-40
have been found in morbidly obese patients [33]. MCP-1
is associated with monocyte trafficking and macrophage
infiltration in adipose tissue [39] and it is also a strong
predictor of cardiovascular death [40]. YKL-40 levels are
elevated in morbidly obese patients, but despite the
apparent linkage between YKL-40 and macrophage matu-
ration and activation, no studies have ever found andCardiovascular Diabetology 2009, 8:61 http://www.cardiab.com/content/8/1/61
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association between YKL-40 and body mass index
[31,33,37].
YKL-40 in endothelial dysfunction and atherosclerosis
The participation of YKL-40 in inflammatory states and
vascular processes implies that YKL-40 may play a role in
endothelial dysfunction and atherosclerosis. In endothe-
lial dysfunction, elevated YKL-40 levels seem to be
involved in relation to cell migration, reorganization and
tissue remodelling as a response to endothelial damage
[6,20,41].
In vitro VSMCs from explants of swine thoracic aorta syn-
tesize YKL-40 during the time of transition from monol-
ayer culture to a non-proliferating differentiated
multilayer culture [41,42]. The YKL-40 secretion contin-
ues during the reorganisation of the cells where multicel-
lular nodules are formed. In these nodules the cells re-
express markers of differentiated VSMCs [6,20,41]. This in
vitro nodule forming process mimics some of the charac-
teristics of the in vivo changes that occur in VSMCs follow-
ing injury, where media smooth muscle cells
dedifferentiate, migrate and contribute to the process of
restenosis and neointima formation [43].
In vitro studies also show that YKL-40 promotes chemo-
taxis, cell attachment, spreading and migration of vascular
endothelial cells which suggest a role of YKL-40 in the
atherosclerotic plaque formation, where smooth muscle
cells are induced to migrate through the intima in
response to exogenous signals [20]. YKL-40 also modu-
lates vascular endothelial cell morphology by promoting
the formation of branching tubules, indicating that YKL-
40 has a role in angiogenesis by stimulating the migration
and reorganization of VSMCs [20]. These in vitro studies
are supported by immunohistochemical analysis which
has shown in vivo protein expression of YKL-40 in human
smooth muscle cells in atherosclerotic plaques [19].
YKL-40 mRNA expression is highly up-regulated in dis-
tinct subsets of macrophages in the atherosclerotic
plaque, a plaque that is characterized by the infiltration of
monocytes into the subendothelial space of the vessel
wall and a subsequent lipid accumulation in the activated
macrophages. Particularly macrophages that infiltrate
deeper in the lesion show high YKL-40 mRNA expression
and the highest expression is seen in macrophages in the
early lesion of atherosclerosis [22]. An in vitro study with
emphasis on biomarker discovery for atherosclerosis by
proteomics, show elevated YKL-40 levels in the superna-
tant of macrophages following treatment with oxidized
low-density lipoprotein, a process that mimics the forma-
tion of "foam cells" [44]. This also suggests a role of YKL-
40 in the differentiation of monocytes to lipid-laden mac-
rophages during formation of the atherosclerotic plaque.
YKL-40 in cardiovascular disease
In the last few years, several clinical studies have described
elevated YKL-40 levels in several cardiovascular condi-
tions as well as described an association between YKL-40
and mortality. Studies show, that elevated YKL-levels are
independently associated with the presence of CAD
[35,36,45]. One study even found, that YKL-40 levels
increase with the extent of CAD defined by the number of
stenosed vessels as assessed by coronary angiography [35].
This findings indicate, that plasma YKL-40 levels could be
a quantitative indicator of disease progression as well as of
disease presence [35].
In patients suffering myocardial infarction (MI) even
higher YKL-levels have been documented [36,45,46] and
YKL-levels remain higher in patients with prior MI com-
paired to individuals without previous MI [45]. There
seems to be no difference in YKL-40 levels between MI
patients with or without ST elevations, but higher YKL-40
levels were seen in thrombolyzed patients compared with
non-thrombolyzed patients during the first 24 hours after
the event [46] indicating that YKL-40 is released from the
dissolved thrombosis. Lately, elevated YKL-40 levels have
also been documented in individuals with atrial fibrilla-
tion (AF) where the highest YKL-40 levels were found in
patients with permanent AF compared to patients with
persistent AF suggesting an association between the chro-
nicity of AF and the inflammatory burden [34].
Elevated YKL-40 levels have also been found to be associ-
ated with all-cause as well as cardiovascular mortality in
patients with stable CAD [45]. Furthermore, increasing
mortality rates with increasing YKL-40 levels at baseline
are also seen over a 5 year period in the general popula-
tion above 50 years of age without known diabetes or
CVD (Figure 1) in which YKL-40 were also found to be an
independent predictor of overall as well as of cardiovascu-
lar mortality (Table 1) [32].
All together these findings suggest YKL-40 as a possible
screening modality/diagnostic marker for progressing cor-
onary atherosclerosis. It seems reasonable to speculate
that serum YKL-40 could be used for monitoring the effi-
ciency and sufficiency of medical treatment of patients
with CAD and thereby assist the clinician in reducing the
high occurrence of fatal cardiovascular events.
YKL-40 and diabetes
Individuals with diabetes have in general a 2- to 4-fold
increased risk of subsequent CVD [47]. Persistent micro-
albuminuria is associated with an increased risk of CVD in
both patients with type 1 and type 2 diabetes [48-50].
Patients with type 1 diabetes have up to a 9-fold increased
mortality risk from ischemic heart disease, excessively
higher in patients under 30 years of age [51].Cardiovascular Diabetology 2009, 8:61 http://www.cardiab.com/content/8/1/61
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It has been demonstrated, that patients with type 1 diabe-
tes as well as patients with type 2 diabetes have elevated
plasma YKL-40 levels [31-33,37,52]. In type 2 diabetes
patients YKL-40 levels are correlated with insulin resist-
ance [31,37] and in a single study also with the diabetic
lipid profile [31]. Some studies have also shown a correla-
tion between YKL-40 and glycemic parameters such as
hemoglobin A1c [52] and fasting glucose [37] whereas
others have not [31,33].
In patients with type 1 diabetes a positive association
between elevated plasma YKL-40 levels and increasing lev-
els of albuminuria has been described (Figure 2) [52].
This finding indicates a role of YKL-40 in the progressing
vascular damage in the kidneys resulting in complicating
microvascular disease. This hypothesis is supported by the
finding that YKL-40 and urinary albumin/creatinine ratio
(UACR) are independent markers with only weak inter-
correlation that seem to predict overall as well as cardio-
vascular mortality in a synergistic way in the general
population above 50 years of age without known diabetes
or CVD over a 5 year period (Table 2) [32].
A study of polymorphisms of the CHI3L1 locus encoding
the inflammatory protein YKL-40 did not show any asso-
ciation between certain gene polymorphisms and the risk
of type 2 diabetes. It therefore seems reasonable, that it is
the low grade inflammation and endothelial dysfunction
progressing to later micro- and macrovascular complica-
tions that account for the elevated YKL-40 levels in dia-
betic patients.
YKL-40 in other clinical conditions
Serum YKL-40 levels have been found to be elevated in
other clinical conditions not directly related to atheroscle-
rosis or cardiovascular disease. Several studies describe
elevated YKL-40 levels in patients with different types of
cancer [9,11,53]. YKL-40 levels seem to be related to
tumor grade and burden, short recurrence-free interval
and short disease-free and overall survival [11]. The exact
biological function of YKL-40 in cancer is unknown, but
YKL-40 seems to play an important role in tumor inva-
sion. The signalling pathways MAPK/ERK1/2 and PI3K/
AKT which YKL-40 has been demonstrated to mediate its
effects through in other conditions [26,28] are critical in
the malignant phenotype of glioblastoma and have been
shown to govern proliferation and survival, invasiveness
and radiation resistance [54]. Furthermore, activation of
Table 1: Hazard ratios for cardiovascular and overall mortality at 5 years follow-up in accordance to baseline values of YKL-40 in a 
representative group of the general population without known cardiovascular disease or diabetes
HR (95% CI)
Cardiovascular mortality P value Overall mortality p value
Unadjusted 2.16 (1.67-2.80) < 0.0001 2.29 (1.53-3.44) < 0.0001
Age- and sex-adjusted 1.75 (1.29-2.37) < 0.0001 1.99 (1.26-3.16) 0.003
Mutivariable model 1.57 (1.16-2.14) 0.004 1.57 (1.00-2.46) 0.049
1 SD increase in ln variable.
N = 482, cardiovascular mortality events = 22, overall mortality events = 45.
* Variables: hypertension, total cholesterol, smoking, hsCRP, NT-proBNP and UACR.
Abbreviations: CI, confidence interval; HR, hazard ratio; hsCRP, high sensitive C-reactive protein; NT-proBNP, N-amino terminal fragment of the 
prohormone brain natriuretic peptide; UACR, urinary albumin/creatinine ratio.
Kaplan-Meier-curves of the unadjusted cumulative overall  survival according to increasing quartiles of YKL-40 at base- line (59.5 ng/ml) Figure 1
Kaplan-Meier-curves of the unadjusted cumulative 
overall survival according to increasing quartiles of 
YKL-40 at baseline (59.5 ng/ml). Curves presented from 
top: The mortality rate was 1) 7.6% for first quartile values of 
YKL-40 (≤ 39 ng/l); 2) 9.3% for second quartile values of 
YKL-40 (39.1-59.5 ng/l); 3) 18.5 % for third quartile values of 
YKL-40 (59.6-111 ng/l), and 4) 29.3 % for four quartile values 
of YK-40 (> 111 ng/l), p < 0.0001. Y-axis represents the life-
time of the participants during the 5 years follow-up period.
 
Lifetime, years
6 5 4 3 2 1 0
C
u
m
u
l
a
t
i
v
e
 
S
u
r
v
i
v
a
l
1,0
,9
,8
,7
,6
1 
 
2 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
4 
P<0.0001Cardiovascular Diabetology 2009, 8:61 http://www.cardiab.com/content/8/1/61
Page 5 of 7
(page number not for citation purposes)
the PI3K/AKT-pathway is correlated with increased tumor
grade, lesser likelihood of apoptosis and decreased overall
survival [54]. However, the functional ligand for the chi-
tin-binding site in YKL-40 in relation to cancer is not pres-
ently known.
Recently, an in vitro study has shown, that ectopic expres-
sion of YKL-40 in breast and colon cancer cells respec-
tively led to tumor formation with an extensive
angiogenic phenotype and that recombinant YKL-40 pro-
tein promoted vascular endothelial cell angiogenesis
whereas blockade of YKL-40 suppressed tumor angiogen-
esis both in vitro and in vivo [55]. Furthermore, immuno-
histochemical analysis of human breast cancer showed a
correlation between YKL-40 expression and blood vessel
density [55]. Therefore, the occurrence of high YKL-40 lev-
els in highly differentiated and advanced cancers and
recurrent cancer states could be explained by the role of
YKL-40 in both angiogenesis and fibrogenesis, since
highly differentiated tumours are characterized by high
vascularization and a high turnover of extracellular
matrix.
YKL-40 is not tumor specific and the studies of YKL-40 as
a screening marker for cancer and as a marker useful for
monitoring therapeutic results differ [9]. Furthermore,
YKL-40 seems not suited as a tumor marker due to low
specificity and sensitivity [9].
Conclusion
Substantial evidence supports a role of YKL-40 in
endothelial dysfunction, atherosclerosis and manifest
CVD. Clinical studies have demonstrated, that YKL-40 lev-
els are associated with the presence and extent of CAD, are
even higher in patients with MI and are associated with
all-cause as well as cardiovascular mortality. YKL-40 plays
a role in relation to cell migration, reorganization and tis-
sue remodelling during atherogenesis and seems to play a
pivotal role in the differentiation of monocytes to acti-
vated macrophages in tissues characterized by inflamma-
tion. However, the YKL-40 receptor(s) still remain to be
isolated and described.
YKL-40 has emerged as a promising marker of cardiovas-
cular disease. It seems to be useful for screening because it
is detectable in early stage subclinical disease, and it also
seems to have the potential of becoming a prognosticator
of cardiovascular events and mortality. Future research
around YKL-40 should concentrate further on establish-
ing whether YKL-40 could assess the value of a cardiovas-
Table 2: Unadjusted cumulative cardiovascular and overall mortality according to YKL-40 levels and UACR above and below median 
at baseline in a representative group of the general population without diabetes, hypertension or CVD
Cardiovascular mortality*, % Overall mortality*, %
YKL-40 < median, UACR ≤ median 0.7 4.4
YKL-40 > median, UACR ≤ median 1.1 8.0
YKL-40 ≤ median, UACR > median 3.0 7.6
YKL-40 > median, UACR > median 10.6 30.6
*p < 0.0001 for all comparisons.
N = 389, cardiovascular mortality events = 13, overall mortality events = 44.
Median value of YKL-40, 59.5 ng/ml, median value of UACR, 7 mg/g.
Abbreviation: UACR, urinany albumin/creatinine ratio.
Mean (95% confidence intervals) of ln-transformed YKL-40 Figure 2
Mean (95% confidence intervals) of ln-transformed 
YKL-40. Equivalent YKL-40 data (median (interquartile 
range)), are for macroalbuminuria/diabetic nephropathy (U-
albumin > 300 mg/24 h), YKL-40 = 117 (68-215) ng/ml; per-
sistent microalbuminuria (U-albumin 30-300 mg/24 h), YKL-
40 = 74 (45-160) ng/ml; normoalbuminuria (U-albumin < 30 
mg/24 h), YKL-40 = 53 (32-105) ng/ml; control group, YKL-
40 = 37 (29-52) ng/ml. P < 0.001 for all comparisons. Groups 
were matched according to gender and duration of diabetes 
(> 30 years).
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cular biomarker in clinical practice. Therefore, further
investigations of YKL-40 in relation to CAD, MI and dia-
betes are needed as well as intervention studies describing
possible changes in serum/plasma YKL concentrations
concomitant with optimized medical treatment of condi-
tions such as e.g. angina pectoris and diabetes. Further-
more, to assess the value as a useful marker in clinical
practice, both specificity and sensitivity of YKL-40 in rela-
tion to CVD need to be clarified and optimized.
Studies in obese with and without complications such as
CVD and/or diabetes are few. Such studies could also con-
tribute in establishing YKL-40 as a useful cardiovascular
biomarker, since the weight loss following bariatric sur-
gery is accompanied by a reduced risk of CVD in these
patients. One study has described significantly reduced
YKL-40 levels in obese having bariatric surgery indicating
an association between serum YKL-40 levels and adipose
tissue/weight loss/reduced cardiovascular risk that still
remains to be clarified [33]. Cardiovascular follow-up in
these patients should be done.
Finally, elevated YKL-40 levels have also been observed in
patients with highly differentiated and advanced cancers
of various types as well as recurrent cancer states, but
recent studies show that this could be explained by the
role of YKL-40 in cancer angiogenesis and fibrogenesis.
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